Brainchild of Tom Towey MRCVS, an ECC clinician, the new service allows vets to upload case details, including the level of urgency, and then browse the referral centres that can meet the need, listed by the distance to the practice or to the client and the level of expertise available (eg. Specialist / Advanced Veterinary Practitioner).
You then select the ones that look interesting, press submit, and the request is sent on your behalf.
The referral practices you've contacted can then reply with their estimate for the procedure and details of when they can see the case.
The owner is notified about each new estimate and can decide which to accept.
When they do, the referral clinic then calls the owner to make an appointment.
Tom highlights part of the Competition and Markets Authority provisional report which says:
"10.16: Our provisional view is that, in a well-functioning market, where multiple referral providers are available and clinically appropriate, we would expect pet owners to be made aware that they can choose a referral provider and to be able to access information about those providers including the nature of the treatment, the skills and experience of the referral vet, the availability of appointments, and, in many cases, the likely cost."
Tom's new service seems to fit the bill precisely.
www.rapidreferrals.co.uk
The webinars already available cover subjects like cardiopulmonary resuscitation (CPR), emergency diagnostics and traumatic brain injury, presented by experienced emergency vets Aoife Reid, Liron Levy-Hirsch and Jacqueline Seymour.
More content is due to be added to the library in the coming weeks, including guest webinars from TVM UK on rodenticide and seizure management, and from clinical psychologists Dr Jo Becket and Dr Jess Brown on “thrive, not just survive” and “when stress gets too much”. There will also be a session from ECC specialist Tobias Grave (pictured right) on how to deal with some of the most common pet emergencies.
Tobias will also be on hand to help veterinary surgeons and nurses whose practices use Vets Now for their out-of-hours service with both general advice and a second opinion on potentially complex cases via the new support line.
Tobias said: “Covid-19 is bringing fresh challenges to vets and vet nurses every day. With clinicians seeing a caseload which is mainly emergency and often having to triage patients over the phone or by video consult, it’s never been so important to come together as a profession.
"Both our webinars and our specialist support line for practices who use our service will help equip vet professionals with the skills and knowledge needed to deal with challenging emergencies in practice."
You can find Vets Now’s library of free ECC webinars here.
The stem cells were created as part of a study into feline hypertrophic cardiomyopathy (HCM), which the RVC carried out in association with the Animal Health Trust (AHT), The Beryl Evetts and Robert Luff Animal Welfare Trust (BERLAWT), The Winn Feline Foundation and Boehringer Ingelheim.
The RVC says HCM affects about 15% of the feline population in the UK; translating to over 1 million cats. It is caused by genetic mutations which affect the heart muscle cells.
To date, there are no treatments proven to stop or reverse it, leading to a very poor prognosis for affected cats.
This is partly because a major issue with studying heart diseases at a cellular level is that heart muscle cells do not survive in a laboratory environment. When studying human heart cells, this has been overcome by turning ordinary skin cells into pluripotent stem cells (cells able to turn into any tissue in the body).
These are termed 'induced pluripotent stem cells', or iPSCs. It is then possible to generate heart muscle cells to study from these iPSCs.
The research, carried out by Dr Luke Dutton under the supervision of Professor David Connolly, Dr Jayesh Dudhia and Dr Debbie Guest, as part of his PhD at the RVC in collaboration with AHT, has now identified the conditions required to create iPSCs from domestic cat cells.
While creating iPSCs has been done before in wild cats, the RVC believes that Dr Dutton’s breakthrough in creating iPSCs from domestic cat cells is a world first. It sets the scene for further research into how to turn these iPSCs into heart cells and then, once successful, testing drug therapies that could improve outcomes for cats with HCM.
The researchers say that the translational benefits of this project are potentially very significant, as around 1 in 500 people in the UK have HCM, and the condition manifests in humans in the same way.
If the therapies that researchers test on feline heart cells turn out to be effective, this sets the stage for testing these treatments on humans.
Dr Dutton, author of the study, said: "This is an incredibly exciting project, which is only made possible by the generous funding of the BERLAWT, Boehringer Ingelheim and The Winn Feline Foundation.
"Not only is this study the first reported generation of iPSCs from domestic cats, but these cells can now be used in a novel disease model. This will allow us to study the disease processes present in these cats in ways that have not been possible with the ultimate goal of identifying new therapeutic agents that may slow or even stop the disease process. We would then hope to translate these agents into the feline clinic."
Dr Debbie Guest, Head of Stem Cell Research at the Animal Health Trust, said: "This is the first report on the successful generation of domestic cat iPSCs. These cells not only bring hope to cats suffering from HCM, but allow us to develop new tools to study conditions affecting other tissue types in the future."
Andrew Parry MRCVS, an RCVS and European Specialist, heads Diagnostic Imaging at Willows. He said: "Our previous CT scanner was excellent but all technology moves on. We wanted to ensure we maintained our position at the forefront of specialist veterinary diagnostic imaging.
"We have a large cardiology service and the Siemens scanner, with its advanced cardiac imaging package, will allow the team to gain a huge amount of information about cardiac disease and other vascular abnormalities. This combination of technology and on-site Specialist imaging expertise is unusual, even at a referral level.
"A further advantage of the new scanner is its use of tin filters, which enables it to produce high quality images of regions of high contrast, such as feline chests."
Willows has also invested in a software package which does all sorts of clever stuff to bring the images to life for clients.
He said: “The syngo.via software allows anyone to access and manipulate images from any computer in the hospital. This can be building complex models or more straightforward multiplanar reconstruction.
"Specialists can show models to clients immediately, while surgeons can manipulate images in theatre and all clinicians can view and interact with images from their own working environment.
"Additionally, we have invested in Siemens-manufactured software called syngo.via Cinematic VRT, which means we can build, rotate and fly through volume rendered CT models with clients, giving them a dynamic understanding of anatomy and pathology."
The programme offers a structured and heavily supported first year in practice, including hands-on surgical training and seminars from Advanced Veterinary Practitioners, at the Pets'n'Vets' Roundhouse Veterinary Hospital in Glasgow.
Totally Grad! also includes a mentor plan and additional monthly benchmarking and seminars and support.
Oliver Jackson, partner at Pets'n'Vets said: "We are well aware that many larger veterinary entities run new graduate programmes and we are proud to say that Totally Grad! offers great advantages that come with our independent structure.
"Independent practice can offer a rewarding working environment for new graduates – particularly progressive practices such as ours. We can offer new graduates not only the close-knit, friendly, helpful, stable, first-opinion experience, but also provide opportunities for career growth and development.
"We have the facility for graduates to explore their particular areas of interest. Indeed, in our practice it is possible for a new graduate to change our way of working – the decision-makers are available and listening. We now have many vets working with us who have come through the practice from our graduate system and who have gone on to help shape our practice.
"The success of our Laparoscopic and Cardiology clinics can be attributed to those vets, as can various other client service initiatives and ways of working. New blood brings new ideas and we welcome that."
Totally Grad! will also be open to fellow independent practices.
Oliver added: "By opening up our Totally Grad! programme, we are offering a simple, accessible facility to those fellow independent practices able and willing to provide a mentor and allow their graduate vets to be out of their practice for one or two days per month over a 12 month period. It fits perfectly with our Roundhouse Referrals offering which offers advice, CPD and support to local practices."
Any independent practices interested in participating in the programme can contact oliver.jackson@petsnvets.org while final year students interested in learning more about the programme can visit the website at www.totallygrad.co.uk and/or email Karen W at hello@totallygrad.co.uk
Elanco Companion Animal Health - maker of Comfortis, the flea treatment for dogs - is hosting an online evening webinar on Tuesday 10th January to highlight what pet owners want from their vets.
The free webinar follows research into the perceptions of clients and veterinary surgeons as to what attributes constitute a 'good vet'1. According to Elanco, the research revealed a distinct mismatch between what vets think and what pet owners think. The webinar will highlight these differences and the steps veterinary professionals can take to address them. Additionally, it will provide veterinary professionals with the opportunity to learn more about Comfortis and ask questions of Elanco's technical consultants.
Presented by Alan Robinson BVSc MRCVS DMS, a business development consultant for independent veterinary practices, the webinar will start at 8.00pm and will account for two hours CPD. Veterinary surgeons and nurses wishing to book a place should visit www.thewebinarvet.com/comfortis.
For further information, please telephone 01256 353131, email elancoCAH.uk@lilly.com or contact your local Elanco key account manager.
Christine will take over from Nigel Gibbens who is stepping down at the end of February 2018 after 10 years in the post.
Christine, who comes from a farming family in the south of Scotland, is an experienced veterinary surgeon who worked for a number of years in private practice in Scotland and the north of England, prior to joining the Animal Health agency (now part of the Animal and Plant Health Agency) in 2008 as a Divisional Veterinary Manager in Scotland.
Since 2016, she has been working as the CVO in New South Wales, Australia, where she has led major improvements to biosecurity across many farming sectors.
Christine said: "I am delighted to have been appointed and it will be a privilege to lead my veterinary colleagues to support our farming and food industry in this hugely important role.
"I am very much looking forward to working again with the team at Defra, its agencies, the devolved administrations and all the individuals and groups which will contribute to meet future challenges across animal health and welfare.
"The UK Government has made no secret it wants to cement its place as a world-leader on animal welfare as they leave the European Union, and I’m delighted to have an opportunity to play a part in that."
Nigel said: "I would like to congratulate Christine on her success against a strong field of candidates and I am certain she will be a great addition to the department.
"Her breadth of experience from work within Government and in the private sector will enable her to provide excellent veterinary leadership to the Defra group to deliver government’s ongoing commitment to maintaining our high animal health and welfare standards and to represent the interests of the whole of the UK internationally."
Animal Welfare Minister Lord Gardiner added: "I warmly welcome Christine to her important role. She brings to it a wealth of experience and enthusiasm.
"This Government is embarking on an ambitious programme of animal welfare reform, including plans to increase the maximum sentence for animal cruelty to five years in prison and introducing mandatory CCTV in all abattoirs. Christine will be invaluable in helping us in achieving world leading standards.
"I thank Nigel Gibbens for his outstanding contribution as CVO over the past ten years. Leaving the department at the end of February, he is hugely respected across the veterinary community and beyond – leading on responses to disease outbreaks including avian influenza and advising government on issues from antimicrobial resistance to animal welfare."
British Veterinary Association President John Fishwick said: "We’d like to congratulate Christine Middlemiss on her appointment as the UK’s next CVO and welcome her return to Defra - as well as to the UK, following her 16 months as CVO in New South Wales, Australia.
"As Christine notes, she will take up her role amidst EU Exit negotiations when the vital role veterinary surgeons play in so many areas of political and public life must be championed and considered more than ever.
"The work of all vets in government is indispensable in protecting and promoting animal health and welfare and public health, and current UK CVO Nigel Gibbens CBE has been crucial in steering this with calm direction and sage insight from the heart of government.
"We hope to continue our effective working relationship with the new UK CVO, and really look forward the opportunity to work with Christine moving forwards."
Christine will take up her new role as CVO for the UK on the 1 March 2018.
The programme commences in October 2017 and includes ten days of hands-on practical training based at the CPD Solutions Training Centre in Studley near Birmingham, where surgery tutors will help veterinary surgeons refine their techniques in small group sessions.
CPD Solutions says the main differences with existing PgCert programmes include a stronger emphasis on practical training, a lack of lecture days and the grouping together of practical days in three attendance sessions.
The company says that many current PgCerts run for 2 to five years, so its programme provides an opportunity for those who'd prefer to complete their training and gain a PgCert qualification in a much shorter timeframe.
Susie Coughlan, MD at CPD Solutions said: "Our experience is that vets get the most out of hands-on practical training in a structured and supportive environment, combined with reflective application of their new skills in practice. We set out to replicate this with the new PgCert – all attendance sessions are practical, and the course provides support for developing reflective work-based learning that vets can then use throughout their careers."
David Perrin, Head of Professional Development at the Centre for Work-Related Studies at Chester University said: "The University is proud to be working with CPD Solutions as leading educationalists in the field of veterinary professional development. We have put together a high-quality product that brings together our work-based learning expertise with CPD Solutions specialist knowledge, and this will be of wide interest to practitioners in the field."
For more information, contact CPD Solutions on 0151 328 0444 or visit www.pgcertsurg.com
The awards, which recognise the achievements of remarkable people from the veterinary, farming and charity industries, were hosted by TV presenter and animal lover, Matt Baker, and Chris Laurence MBE FRCVS, who was also chair of the judging panel.
Chris said: "Once again the breadth of nominations for the Welfare Awards has amazed and enthused the judging panel. The new categories this year have been well supported and widened the field of nominees as well as increasing the number of nominations. There have been some outstanding finalists and those who have won should be justifiably proud to have done so against some stiff competition. Of course, the real winners in all this are the animals whose welfare has been improved and the message that has given about the importance of animal welfare to those who have come into contact with all the nominees."
The other award winners were:
Vet Nurse of the Year Award in association with Agria Pet InsuranceRachel Wright, TOLFA
Charity Team of the Year Award in association with PDSAEbony Horse Club, Brixton
Charitable Contribution of the Year Award in association with Blue Cross Fiona Gammell, Wicklow Animal Welfare
Farmer of the Year Award in association with R.A.B.I.David Finlay, Rainton Farm, Castle Douglas
Farm Educator of the Year in association with NADISJames Griffiths from Taynton Court Farm, Gloucester
International Cat Care Welfare of the Year AwardIan MacFarlaine, chief inspector of SPCA in Bermuda
Outstanding Contribution to Animal Welfare Award in association with Your Dog and Your Cat Professor Jacky Reid, Honorary Senior Research Fellow at the University of Glasgow and CEO of the research company, NewMetrica.
Cuneyt Seckin, managing director of Ceva Animal Health UK and Ireland said: "The vision, dedication and hard work demonstrated by each and every award winner is truly outstanding. We had a brilliant evening celebrating our remarkable winners and would like to congratulate each and every one of them on their fantastic achievement."
Photo: Chris Laurence, Adele Waters (Vet Record), Hannah Capon and Matt Baker.
Vetoquinol UK has launched Sodium Salicyl 80%, a water soluble, non-steroidal anti-inflammatory drug (NSAID).
Sodium Salicyl 80% contains 800mg of sodium salicylate and is indicated for supportive treatment of pyrexia in acute respiratory disease in calves (of at least two weeks of age). In pigs, Sodium Salicyl 80% is indicated for the treatment of inflammation, in combination with concurrent antibiotic therapy. Vetoquinol says that unlike acetylsalicylic acid (conventional aspirin) which is poorly soluble in water, sodium salicylate is highly water soluble (1 g/ml water), even in the hard water commonly encountered in the UK which makes it ideal for group therapy in any herd.
Sodium Salicyl 80% can be administered orally through the milk replacer or drinking water. Orally administered salicylates are absorbed rapidly and make it easier to treat groups of pigs and calves suffering from stress.
Vetoquinol says it's well known that any focus of pain or discomfort is likely to reduce an animals' feed and water intake, enough to reduce performance and potentially increase the need for the use of antibiotics. NSAID's are ideal for use in times of stress, for example after weaning where they have the ability to reduce inflammation, provide analgesia and reduce pyrexia. Unlike corticosteroids, NSAID's relieve pain and inflammation without the immunosuppressive and metabolic side effects. Stress is a known cause for an acute phase response (inflammation) and viral and bacterial infections are common in this vulnerable period.
Susan Mitchell, Large Animal Product Manager at Vetoquinol said: 'We are delighted to be expanding our large animal range with Sodium Salicyl 80%. We are now able to offer vets and producers a solution for both individual and group situations where an NSAID is required"
As the company points out, there is a lot of catching up to do as practices return to the new normal, plus a cohort of pet owners who remain at risk or reluctant to visit their vets. Online consultations, phone consultations and home delivery services such as VetPost can help to get the revenue back in to the practice.
Mark Johnston from Video With My Vet said: "Video With My Vet was designed and developed to enable the client to have consultations with their own practice because the client/patient relationship will already be in place, meaning the clinicians at the practice will have the context of the previous consultations and clinical procedures with the practice to refer to."
Vet-AI/Joii co-founder Robert Dawson, said: “Here at Joii we are looking to develop long-term, mutually beneficial relationships with forward-thinking practices, focused on providing fantastic customer care. As a practice owner for 25 years I am very aware of the stresses and strains of normal vet practice life and once lock down is lifted it may not be practicable for most practices to provide dedicated remote care for their patients and clients. We want to integrate with physical veterinary practices to work together to provide the best possible customer journey, where clients can access telemedicine instantly and where any cases needing face to face care can be triaged seamlessly into practice.”
Essentially, the difference between the two propositions is that 'Video With My Vet" is a platform for practices to provide their own telemedicine service for their clients, whereas Vet-AI/Joii provides clients with advice from its own vets, referring them back to their practice as needed.
For further information, contact your Zoetis Account Manager or Customer Services 0845 300 8034.
First you need to complete your VetSurgeon Profile, in particular the last four sections: "Qualified at", "Interests", "Interested in collaborating on" (aka goals) and "Memberships".
Then visit VetSurgeon Connect and click the button marked "Share My Location". This will activate the map beneath, allowing you to see local colleagues with common interests. It will also pin you on the map, but only in front of logged in members of the site with whom you have a common interest.
One area of common interest is the connection between general practitioners and referral practitioners. Referral practitioners who have shared their location are pinned on the map and can be seen by general practitioners (who can also filter them by discipline).
It is hoped that this will help create a more vibrant referral marketplace, as it offers referral practitioners who do not have big marketing budgets a way to connect with local general practitioners.
The system also matches VetSurgeon members by a number of other criteria. So for example, if you specify 'Qualified at' in your profile, it will display anyone else who went to the same vet school. If you display a leisure interest like cycling in your profile, it'll display other vets in your area who also like cycling.
If you display a clinical interest, such as oncology, it'll show you others in the area with the same interest.
The same thing happens with 'Interested in collaborating on', which connects you with others working towards the same goals, which can be business goals like practice ownership or a learning goals, such as CPD or being a mentor/mentee.
Lastly, if you specify your membership of a special interest veterinary association, the system will show you other members who are in your area.
VetSurgeon Editor Arlo Guthrie said: "It’s kind of a professional matchmaking service designed to make it easier than ever before for veterinary surgeons and others to hook up and collaborate on all sorts of different things.
"It may be you think you know everyone you need to know in your area already. But so often we think we know people, then find out we didn’t know about a shared passion for something, whether it be a professional or a leisure interest. Indeed, I think the system could be just as useful in connecting members to go on a bike ride together as it is to help them collaborate on CPD or on achieving additional qualifications."
Chris Taylor from Swann-Morton said: "We are really pleased to be part of this initiative which should help to bring the veterinary community closer together through shared experiences and knowledge."
Arlo added: "I’m very grateful for Swann Morton’s support. If you are too, you can show it by visiting the company's website and having a quick browse of the latest products in its veterinary range at www.swann-morton.com."
The company says industry estimates are that 12 million accessible breeding ewes (91%) are not vaccinated against enzootic abortion in the UK, and that this should concern all practitioners with sheep clients.
Any flock with an abortion rate of over 2% could, it says, be suffering from the disease, and at a cost of £85 per aborted ewe, those are losses producers can ill-afford to ignore.
Stephenie Clarke from Ceva said: "Abortion remains one of the most significant reasons for loss in sheep flocks and an abortion storm can lead to crippling results on farm.
"Enzootic abortion caused by C. abortus remains the main cause of ovine abortion in the UK1 and once in a flock, takes time to control as exposed ewes can become latently infected."
Assure Ewe is a subsidised blood testing scheme open to all flocks with 50 or more breeding ewes. In contrast to other schemes, evidence of an abortion does not need to have taken place.
Blood samples should be collected from six ewes, with full farm and vet details also supplied. Upon results, Ceva says it will share information with the participating veterinary surgeon to discuss with the farmer.
Stephenie added: "Assure Ewe is a very user-friendly, simple scheme that will help facilitate conversations between vets and farmers while, at the same time, providing useful testing information to vets. Ceva encourages evidence based veterinary decisions, and this is just one example of such an initiative."
If C. abortus is identified in a flock, a veterinary-devised plan combining vaccination with Cevac Chlamydia, biosecurity and only purchasing stock from accredited flocks will assist disease control and eventual eradication.
For further information about the scheme, contact your Ceva territory manager.
Reference
Felpreva is the first spot-on parasiticide for cats that covers tapeworms in addition to other endoparasites including gastrointestinal roundworms and lungworms, and ectoparasites (fleas, ticks and mites) for up to three months with a single dose.
It is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections, including:
Matthieu Frechin, Vetoquinol CEO, said: “Marketing authorisation is a pivotal achievement for both Vetoquinol and Felpreva.
"It is a breakthrough treatment with convenience and simplicity of use combined with long-lasting efficacy.
"We believe that Felpreva will be a real game changer for this area of veterinary medicine, demonstrating our commitment to the parasiticide market.”
It is anticipated that Felpreva will be available in Europe early in 2022.
The campaign comprises a series of short videos featuring equine behaviourist Gemma Pearson MRCVS. The videos demonstrate quick and simple ways of teaching horses to be quiet, relaxed and safe for injections, clipping, worming, examinations and other veterinary procedures.
Equine practices can share the video links with clients here.
According to a paper published in the journal Equine Veterinary Education in January, an equine vet may expect to sustain between seven and eight work-related injuries that impede them from practicing, during a 30-year working life.1
This is far a higher figure than other civilian occupations such as the construction industry, prison service and the fire brigade.
Bruising, fracture and laceration to the leg or the head were the most common injuries reported with the main cause being a kick with a hind limb. Nearly a quarter of these reported injuries required hospital admission and 7% resulted in loss of consciousness.
David Mountford, CEO at BEVA said: "Many accidents reportedly occur when vets are trying to work with horses who have learnt to avoid examination or treatment and where handlers are not in full control. Gemma’s work at the Royal (Dick) School of Veterinary Studies and her amazing videos show how a little preparation can have a big impact on horse, owner and vet safety.”
David Catlow, Blue Cross director of clinical services, said: "These videos are a superb resource to help with behaviour training in horses and to help them remain calm and manageable in all sorts of circumstances. Time spent on behaviour training of horses, using positive reinforcement methods such as these, is time well spent for everyone’s safety. Blue Cross invests a great deal of time in behaviour training on the horses we rehome, and it works."
The seven practical videos cover how clients can train and prepare their horse for:
David Mountford added: "These videos make interesting viewing for vets as well as horse owners and build on Gemma’s eBEVA webinar "Practical Equine Behaviour" and the Guidance on Managing Equine Risks that BEVA has produced.”
You can watch the videos here.
Photo: Equine vets Malcolm Morley and Gemma Pearson
The show follows veterinary surgeons and nurses going about their day-to-day work, consulting and operating on a variety of cases from the routine to the extraordinary.
The ten-episode series stars Cat Henstridge, who many will be familiar with for her social media posts as 'Cat the Vet', and her husband Dave Hough who is the Clinic Director at the practice.
Cat said: "I know from the reactions I get on my website and social media channels that there is a huge level of interest in what we do, and the TV programme will help to bring those real-life stories directly to a younger audience, as well as offering exclusive behind the scenes access to everything that happens in our busy veterinary practice."
Dave added: "We are thrilled to be showcasing the fantastic work of our dedicated and talented team. What we see every day is so varied, and we are driven by our love of pets and the ability to help heal them. It’s a real delight to think that our work will be seen on television, and hopefully inspire the next generation of vets, nurses and support staff to work in this really rewarding profession."
Bravecto Triuno is approved for the treatment of tick and flea infestations in dogs (Ctenocephalides felis, C. canis, Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus).
It is also approved for the treatment of infections with roundworms (adult stages of Toxocara canis and Toxascaris leonina) and hookworms (L4, immature adult (L5), and adult stages of Ancylostoma caninum and Uncinaria stenocephala), for the prevention of heartworm disease (caused by Dirofilaria immitis), and for the prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).
Victoria Miles, UK Companion Animal Director, MSD Animal Health, said: “With this latest formulation of Bravecto, MSD Animal Health is giving veterinarians and dog owners a greater range of convenient options for protecting their dog year-round from parasites, and all from the same trusted Bravecto portfolio.”
She added: “We see Bravecto Triuno as a great option for puppies that require a monthly wormer on top of protection against fleas and ticks.
"This also gives flexibility later on for the dog to remain with the Bravecto brand but be swapped onto a longer-duration flea and tick product with a wormer administered according to a veterinarian’s risk-based assessment.”
Bravecto Triuno is available as a flavoured chewable tablet indicated for dogs and puppies from 8 weeks of age and at least 1.27 Kg body weight and can be administered monthly to dogs at risk of infestation by multiple types of internal and external parasites.
It contains three anti-parasitic ingredients including fluralaner, which provides activity against ticks and fleas, moxidectin, which provides systemic activity against non-intestinal worms, and pyrantel, which provides activity against intestinal worms.
https://www.noahcompendium.co.uk/?id=-488423
Floxabactin is indicated for use in dogs with lower UTIs including those associated with prostatitis, upper urinary tract infections caused by Escherichia coli or Proteus mirabilis in dogs, and superficial and deep pyoderma. For cats, the 15 mg dose can be used with upper respiratory tract infections.
Floxabactin is presented in blister packs: 15mg for cats and dogs, plus 50mg and 150mg for dogs.
Dechra Brand Manager Carol Morgan said: “Floxabactin has been developed with the responsible administration of antibiotics in mind. We would always promote only using antimicrobials when an infection has been documented and based on the results of culture and sensitivity testing, and or cytology testing, if applicable.
"Other treatment options should also be considered before the systemic use of antibiotics such as topical treatment for superficial pyoderma."
For more information, visit: https://www.dechra.co.uk/new-from-dechra
In the Somerset cull area, TB incidence has fallen from 24% before culling started to 12% in year four of the cull, while in Gloucestershire it has fallen from 10.4% to 5.6%.
The Government says the findings are in line with expectation based on the scientific evidence from the Randomised Badger Culling Trial which underpins the approach to tackling bovine TB – and demonstrate progress is being made in delivering the 25-year TB eradication strategy in England to rid our farmers of the impacts of this terrible disease.
Defra has also announced additional measures being taken to help control the disease, including licences for badger control in 11 new areas and the opening of a new round of applications for the Badger Edge Vaccination Scheme grants.
Farming Minister George Eustace said: "Bovine TB remains one of the greatest animal health threats to the UK. There is no single measure that will provide an easy answer which is why we are committed to pursuing a wide range of interventions to protect the future of our dairy and beef industries and eradicate the disease within 20 years.
"No one wants to be culling badgers forever so the progress reported today is encouraging."
BVA President John Fishwick said: "We continue to support a comprehensive and evidence-based approach to tackling bovine TB, including the use of badger culling in a targeted, effective and humane manner. TB is a devastating disease and we welcome the positive results emerging in Somerset and Gloucestershire, where licensed culling has now been in place for four years. The recent results in Dorset, indicating a slight upward trend in the incidence of bovine TB, present some cause for concern and we would like to see further investigation of the cattle and wildlife situation in that area.
"BVA supports the principle of badger controls within the Low Risk Areas (LRAs) of England where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy. We are largely reassured by the greater clarity provided on the decision-making process on how and where badger controls will be introduced in the LRAs. We recognise the expertise and professional judgement of veterinary and scientific colleagues in government who have made the decision to extend the cull in this area, but we would welcome further evidence regarding the level of TB infection in the wildlife reserve in Cumbria as this becomes available.
"Halting the spread of bovine TB is essential and it is vital that we use every available tool in the toolbox to support the Government’s aim to make England TB free. We therefore welcome both the introduction of tighter cattle controls where needed and the re-commencement of the Badger Edge Vaccination Scheme, particularly if used as a ‘firebreak’ to mitigate the spread of the disease into the low risk areas. We would also like to see a commitment to funding of further research in this area."
Photo: Coatesy/Shutterstock
Richard was nominated for his dedication to improving rabbit welfare, in particular for his work in getting a new vaccine in to the UK to protect all pet rabbits against an emerging deadly disease (RVHD2).
Richard qualified from Liverpool University in 1994, obtained his Certificate in Zoological Medicine in 2001 and his Diploma in Zoological Medicine in 2010, while he was an RWAF resident. Richard is also registered as a recognised RCVS Specialist in Zoo and Wildlife Medicine (one of only 30 in the world).
Rae Todd, CEO of the Rabbit Welfare Association & Fund said: "We're incredibly proud of Richard for all of his hard work and delighted that he's received recognition for his work. We all owe Richard a huge debt of gratitude for his commitment to the industry and for protecting all pet rabbits. So far, we estimate in the region of 70,000 rabbits have been vaccinated thanks to Richard."
Co-host of the awards, Matt Baker said: "I am truly humbled by the hard work and dedication of individuals and organisations who are passionate about improving animal welfare and would like to congratulate both the finalists and the award winners who are making a real difference to the lives of animals both in the UK and abroad."
Cuneyt Seckin, managing director of Ceva Animal Health, added: "The Ceva Animal Welfare Awards go from strength to strength, both in terms of the number and quality of entries that we receive during the nomination process and the dedication, commitment and enthusiasm of the finalists and winners who often go above and beyond the call of duty in the name of animal welfare."
Other winners this year included:
Welfare Nurse of the Year Award in association with Agria Pet InsuranceAdina Valentine, Blue Cross Animal Hospital in Grimsby
Charity Team of the Year supported by PDSAThe Dog Breeding Reform Group
Charitable Contribution of the Year supported by Blue Cross Helen Whiteside, Canine Research Associate at Guide Dogs
Farm Animal Welfare Award supported by R.A.B.I. and NADISThe University of Nottingham Dairy Herd Health Group
International Cat Care Welfare of the Year AwardMaria Pinto Teixeira from Animals de Rua (AdR) in Portugal
The Disciplinary Committee made its decision last Friday, following an adjournment of the case, which was initially heard in May of this year.
There were three heads of charge against Mr Hough:
The Committee found the majority of the first head of charge not proven, with the exception of the charges that Mr Hough failed to provide and ensure adequate overnight care for Mya and that it was inappropriate and unreasonable for him to plan for the wound management to be undertaken by Mya’s owners following the second procedure on 21 May 2014.
Regarding the second head of charge, the Committee found it proven that Mr Hough did fail to provide information about post-operative care and out-of-hours cover details to Mya’s owners. However it found Mr Hough’s failure to communicate with the owners regarding treatment options and to provide them with adequate information as to Mya’s post-operative condition not proven.
The third head of charge in its entirety was admitted and found proven.
The Committee also found that those charges that were found proven amounted to disgraceful conduct in a professional respect with the exception of Mr Hough’s failure to provide and/or ensure adequate overnight care and his failure to failure to provide out-of-hours details to Mya’s owners.
In deciding on an appropriate sanction, the Committee expressed significant concerns over Mr Hough’s treatment of Mya, in particular his "failure to devise and implement proper and sufficient procedures to ensure that this dog was not released to owners unless it was safe for her to be released and... that the owners were fully advised as to what was required of them."
The Committee felt that Mr Hough had given "insufficient attention" to Mya’s post-operative care but did accept that the conduct represented a single incident. During the course of the hearing the Committee also heard mitigating evidence given on behalf of Mr Hough, with a number of written testimonials as well as witness evidence in support of his clinical expertise and surgical skills.
The Committee accepted that Mr Hough had taken to heart the lessons to be learnt from the charges against him and had implemented a number of written protocols to prevent recurrence of the shortcomings in his treatment of Mya. Furthermore, the Committee also found that Mr Hough had demonstrated insight into the conduct found against him and that he had apologised for the disparaging remarks he made about other veterinary practitioners.
Alistair Barr, chairing the Disciplinary Committee and speaking on its behalf, said: "In short, the Committee is persuaded that Mr Hough has made a good start in putting in place systems to ensure that the interests and welfare of the animals treated at his practice surgeries are not discharged from care until they are fully ready to be discharged and that the owners of such animals will, in future, be fully informed of what might be asked and required of them when their animals are returned into their care after surgery."
He added: "There are no other areas of [Mr Hough’s] professional practices which appear to the Committee to call for improvements. Accordingly, the Committee is persuaded on this evidence that there is reason to believe that the lessons which Mr Hough needed to learn have been learnt and concludes, therefore, that the sanction of a formal and solemn reprimand adequately meets the needs of the public interest in, and requirements of, this particular case. Mya did make a full recovery from her extensive surgery but she and her owners deserved better post-surgery advice and support."
IVC says the new brand will allow better communication for equine teams within the IVC Evidensia group as well as collaboration with the wider equine world.
IVC Evidensia Equine Vets range from graduates to European Specialists, working in both dedicated equine and mixed practice, with all practices supported by the four large equine veterinary referral hospitals in the UK: Donnington Grove Veterinary Group, Fyrnwy Equine Group, Oakham Veterinary Hospital and Pool House Equine.
IVC says the brand's mission is to put the welfare of horses at the heart of everything it does, to providing outstanding continuity of care for all equine species and breeds across the network, to be at the forefront of continual professional development, supporting and facilitating the development of clinical and leadership skills across all their equine teams, and to build the leading network for equine veterinary care across Europe.
Richard Stephenson, Chair of the IVC Evidensia Equine Clinical Board, said: "Our network brings together all forms of equine work from ambulatory practice to some of leading UK equine referral centres.
“It gives support to all our staff in their careers. We facilitate clinical development from the graduate academy, through intern training, residencies and training up to European Diplomat level.
“We provide coaching and leadership, flexible roles and friendly, inclusive teams.”
For more information, visit https://www.ivcevidensia.co.uk/Equine or stand B01 at BEVA 2021 congress.
As part of the campaign, veterinary practices are being urged to measure their feline patients’ blood pressure from seven years of age and above, as recommended by ISFM (International Society of Feline Medicine) 1.
Ceva says it will also continue the Mercury Challenge, its study of feline blood pressure, throughout 2019 to help increase veterinary professionals' confidence in measuring blood pressure and identifying feline hypertension.
The company says that since June last year, 128 practices and over 1,000 cats have participated in the challenge. You can registered to take part at: mercurychallenge.ceva.com, where there's a chance to win diagnostic tools to help diagnose feline hypertension.
Dr Rosanne Jepson, American, European and RCVS Specialist in Small Animal Internal Medicine at the Royal Veterinary College, said: "It is great to see that so many cats (over 1000!) and practices in the UK have been involved with the Mercury Challenge promoting the measurement of blood pressure and detection of hypertension.
"I would urge as many practices as possible to measure blood pressure; it’s simple, quick and easy to perform and means that we can help prevent target organ damage which at its most severe can leave cats sadly blind for the rest of their life. With careful identification and treatment this can so easily be prevented."
To help raise awareness of Feline Hypertension Month, Ceva has produced a range of marketing materials including waiting room displays, a pet owner leaflet and veterinary marketing packs, which are available upon request.
The initiative will be supported with an extensive PR campaign aimed at pet owners, including a radio day starring CBBC’s Rory the Vet.
For more information, contact cevauk@ceva.com or visit mercurychallenge.ceva.com.
References
The BCVSp says the aim of its proposal is to identify practices that offer a multi-disciplinary referral service, to incorporate standards for specialist care and to define training, veterinary and nursing qualifications, behaviours and facilities which optimise management of cases with complex problems and those requiring advanced diagnostic and/or therapeutic approaches.
Terry Emmerson Hospital Director at North Downs Specialist Referrals and BCVSp trustee said: "Increasing numbers of veterinary graduates are choosing to pursue training leading to post-graduate diplomas and RCVS recognition as Specialists.
"Many vets and nurses are working in groups that allow a multidisciplinary approach to be offered to animals with complex problems. We hope that we can devise a new accreditation strand to give the animal-owning public the ability to distinguish multidisciplinary specialist hospitals from general veterinary hospitals in order to make informed choices regarding the veterinary care they wish to access for their animals."
BCVSp has proposed that prior to entry into the new strand, VSH(M)s would first be required to meet the Core, GP and Veterinary Hospital requirements in all of the modules (Small Animal or Equine as appropriate) and achieve Awards Points at Outstanding level in the relevant modules. BCVSp has put forward an outline plan which is currently being considered by the PSG in which VSH(M)s will be required to offer a minimum number of services but there will also be scope for individual units to highlight particular areas of expertise.
Celia Marr, BCVSp Chairman said: "A key element of the strand we are working on is that each service will be led by RCVS Specialists ensuring on-going accreditation of the experience and expertise within the range of services that together underpin a multidisciplinary approach to case management. We have consulted widely amongst our members to reach consensus on the standards each specialist service should be aiming for."
She added: "We hope to work together with the PSG to develop an accreditation within this strand over the next few years, however working through the current PSS modules to Awards Points level is not easy. Specialist-staffed hospitals aiming for the multidisciplinary strand will need to start planning their approach as soon as possible."
Mandisa Greene, Chair of the Practice Standards Group, said: "The RCVS Practice Standards Group welcomes BCSVp’s proposal and the passion of the group for developing this new accreditation level. Both the PSG and the RCVS Standards Committee will be working with the BCVSp to consider the proposal's feasibility, how the accreditation level might be achieved, potential levels of interest and other criteria in the coming months. It is critical that specific criteria which BCVSp and the RCVS Practice Standards Group develop together are clear, transparent and testable."
Photo: Newmarket Equine Hospital
APPA is an oral, patented, fixed-dose combination of two synthetic secondary metabolites of plant origin, apocynin and paenol.
Under the terms of the agreement, AKL’s unnamed partner will fund a study in dogs with naturally occurring OA. The study will compare the efficacy and efficacy duration of APPA with the current standard of care for treating canine OA: non-steroidal anti-inflammatory drugs.
David Miles, AKLRD CEO, said: “Just like humans, millions of dogs suffer intolerable pain and disability because of OA and the current treatments just aren’t as effective or as well tolerated as they need to be. We already know from previous canine studies that APPA reduces pain and has an excellent tolerability profile but this exciting new partnership will allow us to go one stage further and assess sustainability of response.”
The randomised study will assess pain and duration of response as the primary endpoint. Secondary endpoint assessment will include adverse events, quality of life, pharmacokinetics analysis and biomarkers that may enable potential identification of factors predictive of response at treatment onset, or that correlate with response magnitude.
Two separate studies on dogs have already been carried out by researchers at the University of Vienna. The first, an 11-week cross-over study of 32 canines diagnosed with established, naturally occurring OA, showed that APPA provides significant symptom relief in clinical canine OA1.
A follow-up, five-week study of 60 dogs with OA compared APPA to the standard of care drug, meloxicam. It concluded that daily oral administration of APPA was effective as a stand-alone alternative to NSAIDs in dogs with naturally occurring OA. Significant benefits were also seen for APPA over meloxicam in orthopaedic examination as well as in lameness and function scores2.
The results will inform the pivotal clinical trial design and AKL says its working assumption is that a 26-week field study would complete the regulatory requirements for commercialisation.
If the study and future testing is successful, AKL estimates that APPA would be well placed to capture a significant share of the global canine OA market, which is estimated to be worth $3billion by 20283.